Yehiel Tal

3D Systems and CollPlant Biotechnologies linked

Posted on Updated on

CollPlant Biotechnologies is a partner in the Advanced Regenerative Manufacturing Institute (ARMI), a public-private partnership established in 2017 as part of the Manufacturing USA network. ARMI is focused on developing and commercializing advanced manufacturing technologies for regenerative medicine.

As a partner in ARMI, CollPlant Biotechnologies is working with other organizations to develop new tissue engineering and regenerative medicine technologies. Specifically, CollPlant is contributing its expertise in producing recombinant human collagen, which can be used as a building block for creating various tissues and organs.

CollPlant’s partnership with ARMI is an essential part of the company’s strategy to expand its capabilities in regenerative medicine and bring its products to market. By working with other leading organizations in this field, CollPlant hopes to accelerate the development of new therapies that can improve patient outcomes and quality of life.

As mentioned by Chuck Hull, co-founder and chief technology officer, 3D Systems, “is excited to work with CollPlant to develop groundbreaking bioprinted tissue and scaffold technologies. We believe 3D printing to be a key technology for regenerative medicine, and this collaboration is one of many we are entering to play an integral role in this exciting field. Combining our innovative 3D printing technologies with CollPlant’s rhCollagen-based BioInks has the potential to make a significant impact in bioprinting and regenerative medicine. ”

As said by, “Yehiel Tal, CollPlant’s Chief Executive Officer, “CollPlant is very pleased to enter into this collaboration with ARMI and its network of partners from industry, academia, and the U.S. federal government. We all share the common goal of advancing 3D bioprinting and next-generation manufacturing of tissues and organs. We believe CollPlant’s BioInks, based on our rhCollagen, are the ideal building block for tissue and organ manufacturing, and we are proud to contribute our expertise and to advance the entire science and industry of bioengineering and manufacturing. CollPlant is honored to be a part of this network of industry leaders.”


3D Systems and CollPlant Biotechnologies Join Forces to Accelerate Breakthroughs in Regenerative Medicine


CollPlant Partners in the Advanced Regenerative Manufacturing Institute

3D Bioprinting of tissues and organs

Posted on Updated on

CollPlant is a biotechnology company that develops and produces proprietary plant-based recombinant proteins for medical and aesthetic applications. The company specializes in developing plant-derived collagen for tissue engineering and regenerative medicine. CollPlant’s proprietary technology platform involves genetically engineering plants to produce human collagen, which can be used to create implantable tissues for various medical applications. CollPlant’s products are intended to address a range of medical conditions, including wound healing, orthopedics, and aesthetics.

According to Yehiel Tal, the Chief Executive Officer of CollPlant, “This fundraising is intended to support the advancement of our pipeline in the fields of medical aesthetics and 3D bioprinting of tissues and organs. We are now focused on facilitating our development programs of dermal fillers and regenerative breast implants. Our collaboration with United Therapeutics, which is using our BioInk technology for 3D printing lungs, is progressing, and we continue to expand our business collaborations with large international healthcare companies that seek to implement our revolutionary regenerative medicine technology. We are very pleased to have entered into this transaction with Mr. Sagi and the other investors.”

Eran Rotem, Deputy CEO & CFO. CollPlant Biotechnologies Raising $5.5 Million.